Relacorilant

URI: https://gptkb.org/entity/Relacorilant
GPTKB entity
Statements (25)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkb:drug
gptkbp:ATCCode none (as of 2024)
gptkbp:CASNumber gptkb:1496510-51-0
gptkbp:clinicalTrialPhase Phase 2 (solid tumors)
Phase 3 (Cushing's syndrome)
gptkbp:developedBy gptkb:Corcept_Therapeutics
gptkbp:hasMolecularFormula C27H27F4N3O3
gptkbp:hasSMILES C1=CC(=CC=C1C#N)NC(=O)C2=CC3=C(C=C2)C4(CC5=CC=CC=C5C6=CC=CC=C64)C3
gptkbp:investigatedBy gptkb:cancer
gptkb:Cushing's_syndrome
adrenocortical carcinoma
solid tumors
gptkbp:IUPACName (4aR,6aS,6bS,8aR,10aS,12aR,14aS,14bR)-N-(4-cyanophenyl)-6a,8a,10a,12a,14a,14b-hexafluoro-2,4,4a,5,6,6a,6b,7,8,8a,9,10,10a,11,12,12a,13,14,14a,14b-icosahydro-1H-pyrazolo[3,4-g]isoquinoline-3-carboxamide
gptkbp:legalStatus investigational
gptkbp:mechanismOfAction gptkb:glucocorticoid_receptor_antagonist
gptkbp:molecularWeight 517.52 g/mol
gptkbp:PubChem_CID gptkb:CHEMBL4297592
71587768
gptkbp:routeOfAdministration oral
gptkbp:synonym CORT125134
gptkbp:UNII 6Q1K1VJ0ZV
gptkbp:bfsParent gptkb:Corcept_Therapeutics
gptkbp:bfsLayer 7
https://www.w3.org/2000/01/rdf-schema#label Relacorilant